Ultragenyx Pharmaceutical Inc.
GTX-102
Angelman syndrome
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for GTX-102 in Angelman syndrome are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Data from the fully enrolled, pivotal, Phase 3 Aspire study in patients with a genetically confirmed diagnosis of UBE3A deletion is expected in the second half of 2026.”